INCY News and Press, Incyte Corporation From 04/09/21

The FDA feedback on an upcoming regulatory review and differing opinions on commercialization prospects of key therapies are some of the reasons for analysts to change their outlook on stocks today. Provention Bio sinks further as RBC downgrades it on FDA feedbackProvention Bio (PRVB) ha...

Eli Lilly (LLY) and Incyte (INCY) announces results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg plus standard of care (SoC), including corticosteroids and remdesivir vs. placebo plus SoC.The trial did not meet statistical significance on the primary endpoint - a diff...

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients - Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ven...

Eli Lilly (LLY) and Incyte (INCY) announce that the U.S. FDA has extended the review period for the supplemental New Drug Application ((sNDA)) for baricitinib for the treatment of adults with moderate to severe atopic dermatitis ((AD)).The Prescription Drug User Fee Act ((PDUFA)) action ...

Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis PR Newswire INDIANAPOLIS , April 6, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and In...

In March, I continued to use a strategy of holding income funds and swing trading S&P 500 stocks to realize profits. I closed 16 stock/ETF trades in March for a net gain, including dividends, of 40.68% (median), or 29.56% (cost-weighted), for an average of 10 months in the trades....

Incyte ([[INCY]] -0.8%) announces that the European Commission ((EC)) has approved Pemazyre (pemigatinib) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 ((FGFR2)) fusion or rearrangement that have progres...

- Pemazyre is the first targeted therapy approved in the EU for this indication Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Pemazyre ® (pemigatinib) for the treatment of adults with locally advanced or metastatic cholangiocarc...

The Japanese Ministry of Health, Labour and Welfare ((MHLW)) has approved Incyte's (INCY) Pemazyre, a selective fibroblast growth factor receptor ((FGFR)) inhibitor, for the treatment of patients with unresectable biliary tract cancer ((BTC)) with FGFR2 fusion gene, worsening after ...

Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre ® (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of patients with unresectable biliary tract cancer (BTC)...